Related Experiment Video
Updated: May 9, 2026
06:01
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
[Antithrombotic medications and childhood stroke]
Stéphane Chabrier1, Manoëlle Kossorotoff, Stéphane Darteyre
1CHU de Saint-Étienne, hôpital Bellevue, service de médecine physique et de réadaptation pédiatrique et Centre national de référence de l'AVC de l'enfant, 42055 Saint-Étienne, France; Université Saint-Étienne, EA3065 Groupe de recherche sur la thrombose, 42023 Saint-Étienne, France.
Presse Medicale (Paris, France : 1983)
|July 24, 2013
Summary
Pediatric stroke guidelines are updated using limited evidence, recommending anticoagulation for cerebral sinovenous thrombosis and aspirin for arterial ischemic stroke recurrence prevention in children.
Area of Science:
- Neurology
- Pediatrics
- Vascular Medicine
Context:
- Childhood stroke affects 500-1000 children annually in France, often resulting in persistent neurological deficits.
- Current pediatric stroke guidelines rely on observational data, adult recommendations, and expert consensus due to a lack of high-level evidence.
Purpose:
- To review current evidence and expert opinion on managing pediatric stroke.
- To highlight treatment considerations for specific pediatric stroke types, including cerebral sinovenous thrombosis and arterial ischemic stroke.
- To identify gaps in knowledge and advocate for improved research methodologies in pediatric stroke.
Summary:
- Anticoagulation is recommended for acute pediatric cerebral sinovenous thrombosis, with individualized treatment duration.
- Aspirin effectively reduces recurrence risk in pediatric arterial ischemic stroke.
- Thrombolysis and mechanical devices show potential for recanalization but lack sufficient evidence for widespread pediatric use.
- Neonatal stroke management remains unclear.
- Development of new studies focusing on easily administered antithrombotic drugs and rare disease populations is needed.
Impact:
- Informs clinical practice for pediatric stroke management.
- Highlights the need for evidence-based guidelines tailored to children.
- Guides future research directions for antithrombotic therapies in pediatric stroke.
- Emphasizes the importance of specialized trial designs for rare pediatric conditions.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:29Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...